ADDENDUM - MEDICAL AND HEALTH CONSEQUENCES OF DRUG ABUSE PROGRAMANNOUNCEMENT (PA-96-010)

 

NIH Guide, Volume 26, Number 5, February 14, 1997

 

P.T. 34



Keywords:

  Drugs/Drug Abuse 

  0765034 

  Epidemiology 

  Etiology 

 

National Institute on Drug Abuse

 

PURPOSE

 

This notice is an addendum to program announcement Medical and Health

Consequences of Drug Abuse, PA-96-010, published in the NIH Guide,

Vol. 24, No. 42, December 8, 1995. The purpose of this addendum is to

encourage research on the occurrence and distribution of drug-abuse

related morbidity and mortality in both clinical and large

population-based epidemiologic studies, as well as clinical studies

of the natural history and etiology of morbidity and mortality

associated with drug abuse.  This includes surveillance studies, such

as incidence and prevalence studies in general populations or

subpopulations of drug users, as well as biomedical studies within

clinical settings, such as primary care or drug treatment programs.

 

RESEARCH OBJECTIVES

 

Systematic efforts are needed to respond to a lack of current

information on the morbidity and mortality associated with patterns

of drug abuse.  Data on morbidity and mortality are needed on the

infectious, neurologic, psychiatric, obstetric/gynecological,

neonatal, and other pathophysiological consequences of drug abuse.

The need for new data arises in part from multiple dynamic factors

which influence drug abuse related morbidity and mortality.  Such

factors include: 1) the availability of new drugs and drug

combinations, 2) routes of drug administration, 3) hygienic

practices, 4) drug-related violent behaviors, 5) access, utilization,

and availability of care, 6) emergence of new pathogens and

resistance patterns, and 7) drug abuse patterns related to cultural,

immigration and travel patterns.

 

Types of currently funded studies appropriate for supplementation

include:

 

1) Cohort studies of drug users which are examining the natural

history of HIV disease in both seronegatives and seropositives; 2)

Large population-based studies of the treatment careers or natural

history of drug abuse

3) Health services research studies of access, availability,

utilization, and effectiveness of medical and mental health services

to drug users;

4) Community outreach and intervention studies which identify

populations of active drug users otherwise difficult to access

through drug treatment or primary care; and

5) Community epidemiology studies focused on identifying emerging

patterns of drug abuse and/or HIV/AIDS.

 

SPECIAL REQUIREMENTS

 

BUDGET/ADMINISTRATIVE ISSUES

 

There are no set-aside funds for this effort.  Funding for the

supplements is subject to availability of  research program grant

funds.  Competing supplements are provided for expansion of a

project's scope or the research protocol.  These are treated as new

applications for purposes of the review requirements and competition

for funds, and are reviewed in accordance with NIH standard

procedures, i.e., peer review/council review.  Competing renewal

supplement requests must be submitted in accordance with standard

receipt dates; March 1, July 1, and November 1.  Administrative

supplements are provided to cover unanticipated cost increases that

are associated with achieving the objectives within the original

scope of a project, and include cost increases that result from

making modifications in the scope of a project in order to take

advantage of opportunities that would increase the value of the

project consistent with its originally approved objectives and

purposes.  Administrative supplemental funding is generally limited

to 25 percent of the Council-approved direct costs of the project or

$100,000, whichever is less.  These applications undergo program,

grants management, and budget review within NIDA and may be submitted

for the remainder of FY 1997, but no later than August 1, 1997.

 

INQUIRIES

 

Inquiries concerning this announcement are encouraged.  The

opportunity to clarify any issue or questions from potential

applicants are welcome.  For programmatic issues, contact:

 

Jag Khalsa, Ph.D.

Division of Clinical and Services Research

National Institute on Drug Abuse

5600 Fishers Lane, Room 10A-08

Rockville, MD  20857

Telephone:  (301) 443-1801

FAX:  (301) 594-6566

Email:  jk98p@nih.gov

 

For fiscal matters, contact:

 

Gary Fleming, J.D., M.A.

Grants Management Branch

National Institute on Drug Abuse

5600 Fishers Lane, Room 8A-54

Rockville, MD  20857

Telephone:  (301) 443-6710

Email:  gf6s@nih.gov

 

.

Return to 1997 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.